article · International Journal of Secondary Metabolite
Methanol extracts from the aerial parts of Globimetula oreophila and the leaves of Solanum erianthum were evaluated for their in vitro antidiabetic and antioxidant properties. Both botanical extracts demonstrated radical scavenging activity, recording 23 and 39.8 micrograms per millilitre respectively, alongside total phenolic contents of 44.2 and 24.0 milligrams gallic acid equivalents per gram. Toxicity assessments via the brine shrimp lethality assay demonstrated low toxicity profiles, with LC50 values of 993.5 and 387.4 micrograms per millilitre compared to the reference compound cyclophosphamide. Both extracts also exhibited notable inhibitory action against the carbohydrate-digesting enzyme alpha-amylase, producing IC50 values of 3.052 and 5.544 micrograms per millilitre against acarbose. Analytical chromatography identified 12 pharmacologically active compounds in G. oreophila and 10 in S. erianthum, showing their potential as alternative antidiabetic resources.
Standard diabetes medications are frequently limited by adverse side effects that reduce treatment adherence. Finding natural plant extracts that inhibit key metabolic enzymes offers an alternative pathway to blood sugar management. Establishing that these two plants possess enzyme-inhibiting capacity, antioxidant activity, and low toxicity provides early evidence that may support future therapeutic alternatives with potentially fewer complications for patients.
This research represents early-stage laboratory exploration that could inform pharmaceutical and nutraceutical drug discovery programmes targeting diabetes. If developed, the extracts or isolated constituents could serve developers of complementary botanical treatments or natural drug leads. However, the work currently remains far from market application, as it is limited to preliminary in vitro chemical and enzymatic assays alongside invertebrate toxicity screening, requiring extensive in vivo testing and clinical trials.
AI-generated from the published abstract. Always read the original work before citing.
Diabetes is the most common endocrine disorder globally, and adverse side effects frequently hinder the effectiveness of current diabetes pharmacotherapies. The study was therefore carried out to assess the in vitro antidiabetic and antioxidant potential of Globimetula oreophila aerial parts and Solanum erianthum leaves extracts, as well as analyze the bioactive compounds using an analytical high-pressure liquid chromatography (HPLC) coupled with an ultraviolet-visible (UV-VIS) detector and an online library. The toxicity of the plant extracts was also determined using the Brine Shrimp Lethality Assay (BSLA). G oreophila and S. erianthum displayed a radical scavenging activity of 23±0.34 and 39.8±0.63 µg/mL, in comparison with the positive standard, ascorbic acid, 1.517±0.12 µg/mL. The extracts exhibited a total phenolic content of 44.2 and 24.0 mg GAE/g, respectively. The BSLA results showed LC50 values of 993.5 and 387.4 µg/mL, compared with the positive standard, cyclophosphamide, LC50=16.3 µg/mL. The extracts also showed a notable enzyme-inhibitory effect (IC50=3.052 and 5.544 µg/mL) on α-amylase as compared to the positive control, acarbose, with an IC50=0.18 µg/mL. In the HPLC analysis of G. oreophila and S. erianthum, the UV-VIS detector detected 25 and 32 peaks, respectively; however, based on the reference library, 12 and 10 compounds with pharmacological potential were identified. Thus, these medicinal plants could serve as a natural alternative or complement to conventional diabetes medications, potentially reducing side effects. Moreover, it may lead to the discovery of novel bioactive compounds that can be utilized in drug development.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21448/ijsm.1746441
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
